Stéphane MENDRAS

Pleryon Therapeutics is a preclinical stage biotech startup company. Our mission is to develop novel polymer-based therapeutics to address global unmet medical needs related to aging. Since its formal operation in 2020, Pleryon has raised closed to RMB 100 million from top biotech private investors. Pleryon is advancing its diverse pipelines in multiple disease areas, including ophthalmology, orthopedics, and tissue regeneration.

Pleryon Therapeutics is a preclinical stage biotech startup company. Our mission is to develop novel polymer-based therapeutics to address global unmet medical needs related to aging. Since its formal operation in 2020, Pleryon has raised closed to RMB 100 million from top biotech private investors. Pleryon is advancing its diverse pipelines in multiple disease areas, including ophthalmology, orthopedics, and tissue regeneration.

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market. Our vision is to eliminate preventable blindness. By transforming the delivery of todays eye-care, we are improving patient access to intuitive and affordable diagnostics and treatments. We believe it should be easy for doctors to deliver superior outcomes to their patients. Our technology empowers patients to care for their own vision in between doctors visits. To accomplish these goals, we develop, market and commercialize transformative innovations in diagnostics, sensing, and preventative / medical / surgical treatments for eye diseases. We were formed in August 2020 as a joint venture between Verily Life Sciences, an Alphabet company, and Santen, a leading Japanese pharmaceutical company. We are passionate and committed to building and sustaining an inclusive and equitable working environment. Every member on our team enriches our diversity by exposing us to a broad range of views that help us understand and engage with the world, identify challenges, and to discover, design and deliver solutions. The Twenty Twenty work environment empowers our team to do their absolute best work.

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

XCELENS RESEARCH AND DEVELOPMENT - IS A SWISS MANUFACTURING MULTINATIONAL COMPANY, FOCUSING ON DEVELOPING AND MANUFACTURING OF THE COMPLETE RANGE OF AESTHETIC PRODUCTS, INCLUDING: DERMAL FILLERS, SKIN BOOSTERS AND THREADS